LCA-0061 for Peanut Allergy
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 1combined single ascending dose (SAD)/multiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).
Who Is on the Research Team?
Nadia Tchao, MD
Principal Investigator
Lycia Therapeutics, Inc.
Are You a Good Fit for This Trial?
This trial is for people with atopic conditions (like allergies, asthma, or eczema) and those with peanut allergy. Participants must generally be in good health aside from their allergic condition.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- LCA-0061
Trial Overview
The study is testing different single and multiple doses of a new drug called LCA-0061 given as an injection under the skin, compared to a placebo. The main goal is to see if it's safe and how the body reacts to it.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Participants in cohorts 1-4 will receive multiple ascending dose levels of LCA-0061
Participants in cohorts 1-5 will receive single ascending dose levels of LCA-0061
Participants in cohorts 1-4 will receive multiple doses of Placebo
Participants in cohorts 1-5 will receive a single dose of Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lycia Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.